The latest in premature ejaculation (PE) news reveals positive results for Zertane, a new premature ejaculation treatment that has just been through phase III clinical trials. It was tested at both a low dose and at a high dose. Ampio Pharmaceuticals, the manufacturers, are now eager to get this drug on the market in Europe and Asia.
The success of the drug is measured on the length of time the penis can penetrate the vagina before ejaculating. This is described as intravaginal ejaculatory latency time (IELT). The lower dose lengthened the mean IELT by 4.07 times the length of time observed at the trials outset. The higher dose increased the mean IELT by 4.26 fold.
Men in the group whose median IELT was less than 60 seconds at the baseline experienced even greater benefits from the drug where the IELT increase was at 5.2 fold on the lower dose and 6.0 fold on the higher dose.
Priligy is the only oral drug that has been approved for the treatment of premature ejaculation. Considering Zertane appears to be even more effective than Priligy, the drug stands to do very well in this emerging treatment area.
It is estimated that 23% of men suffer from premature ejaculation (defined as reaching orgasm within 2 minutes of penetration) so this is a potentially large market. As Zertane contains Tramadol Hydrochloride as the active ingredient, we believe that the approval should be fast tracked in Europe as Tramadol has been used for a number of years as a pain killer. This is definitely one to watch.